Meiwei Biotech: Application for Clinical Trials of Injected 6MW5311 Accepted by National Medical Products Administration.

Maiwei Biology announced that recently, the company received a "Notice of Acceptance" issued by the National Medical Products Administration. The clinical trial application for injection use of 6MW5311 for the indication of blood tumors has been formally accepted. At the same time, the application for clinical trials of 6MW5311 in the United States is currently in the pre-IND stage, and is planned to be formally submitted to the FDA in the second quarter of 2026.